Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

71.73
+0.35000.49%
Volume:181.80K
Turnover:13.07M
Market Cap:2.45B
PE:-11.09
High:72.73
Open:70.41
Low:70.00
Close:71.38
52wk High:109.00
52wk Low:27.87
Shares:34.14M
Float Shares:28.53M
Volume Ratio:0.44
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:2.71
PE(LYR):-7.38

Loading ...

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Jul 23

Nektar Therapeutics : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $153

THOMSON REUTERS
·
Jul 22

Nektar Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Jul 22

Cantor Fitzgerald Initiates Nektar Therapeutics at Buy With $153 Price Target

MT Newswires Live
·
Jul 22

Nektar Therapeutics Announces Press Release on Start of Phase 3 Zenith AD Program for Rezpegaldesleukin in Atopic Dermatitis

Reuters
·
Jul 21

Nektar Therapeutics - Zenith Ad Program to Enroll 1,530 Patients Across Three Phase 3 Studies

THOMSON REUTERS
·
Jul 21

Nektar Therapeutics Announces Start of Phase 3 Zenith Ad Program Evaluating Novel Regulatory T-cell Biologic Rezpegaldesleukin in Moderate-to-severe Atopic Dermatitis

THOMSON REUTERS
·
Jul 21

Nektar Therapeutics - Initial Phase 3 Topline Data Expected Mid-2028; Bla Submission Targeted for 2029

THOMSON REUTERS
·
Jul 21

Nektar Therapeutics (NKTR) Stock Looks Above Fair Value Despite Its 7x Run

Simply Wall St.
·
Jul 20

Nektar’s Phase 3 Eczema Bet: What Rezpegaldesleukin Could Mean for NKTR Stock

TIPRANKS
·
Jul 18

Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In?

Simply Wall St.
·
Jul 06

Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Sells 5,681 Shares for $397,670

Reuters
·
Jul 03

Nektar Grants New Hires Options for 20,500 Shares at $60.98 Each Under Inducement Plan

Reuters
·
Jun 27

Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jun 27

Nektar Therapeutics CEO Robin Howard sells USD 1.2 million in common shares

Reuters
·
Jun 19

Nektar Chief R&D Officer Jonathan Zalevsky sells 5,538 shares for $336,412.98

Reuters
·
Jun 18

Nektar grants inducement stock options for 11,900 shares at $69.49 each

Reuters
·
Jun 04

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 04

Nektar Therapeutics to present at Jefferies Global Healthcare Conference via webcast

Reuters
·
May 28

Nektar Therapeutics interim CFO Linda M. Rubinstein files initial beneficial ownership statement

Reuters
·
May 27